To the Editor We have read the article by Ngo Ntjam et al,¹ in which the authors carried out a systematic review and meta-analysis to analyze major adverse cardiovascular events (MACEs) associated with anti–vascular endothelial growth factor (VEGF) injections. Only randomized clinical trials were included in the analysis, and the study concluded that intravitreal anti-VEGF treatment was not associated with an increase in MACEs.

中文翻译：

---

年龄相关性黄斑变性患者死亡率与抗血管内皮生长因子治疗的关系

致编辑我们已阅读 Ngo Ntjam 等人¹的文章，其中作者进行了系统评价和荟萃分析，以分析与抗血管内皮生长因子 (VEGF) 注射相关的主要不良心血管事件 (MACE)。分析中仅包括随机临床试验，该研究得出结论，玻璃体内抗 VEGF 治疗与 MACE 的增加无关。